VivoSim Labs (VIVS) Stock Price, News & Analysis

Company Overview

Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive human liver tissue and ExVive human kidney tissue used for predictive preclinical testing of drug compounds. It is also developing in vivo liver tissues to treat end-stage liver, life-threatening, and orphan diseases. The company was incorporated in 2007 and is headquartered in Solana Beach, California.

Key Stats

• Today's Range: $0.13 to $0.16
• 50-Day Range: $0.13 to $0.30
• 52-Week Range: $0.12 to $3.40
• Volume: 1.15 million shs
• Average Volume: 2.35 million shs
• Market Capitalization: $2.24 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

VivoSim Labs Stock Analysis - MarketRank™

VivoSim Labs scored higher than 5% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

VivoSim Labs has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

VivoSim Labs has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of VivoSim Labs is -0.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of VivoSim Labs is -0.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.96% of the float of VivoSim Labs has been sold short.

Short Interest Ratio / Days to Cover

VivoSim Labs has a short interest ratio ("days to cover") of 0.57, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in VivoSim Labs has recently increased by 8.55%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

VivoSim Labs does not currently pay a dividend.

Dividend Growth

VivoSim Labs does not have a long track record of dividend growth.

News and Social Media

• Score: 2.1 / 5
• News Sentiment: 0.36

News Sentiment

VivoSim Labs has a news sentiment score of 0.36. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.58 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for VivoSim Labs this week, compared to 2 articles on an average week.

MarketBeat Follows

3 people have added VivoSim Labs to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, VivoSim Labs insiders have not sold or bought any company stock.

Percentage Held by Insiders

1.00% of the stock of VivoSim Labs is held by insiders.

Percentage Held by Institutions

8.23% of the stock of VivoSim Labs is held by institutions.

Company Calendar

• Last Earnings: 8/12/2026
• Today: 11/12/2026
• Fiscal Year End: 3/31/2027

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Life Sciences Tools & Services
• Sub-Industry: Life Sciences Tools & Services
• Current Symbol: NASDAQ:VIVS
• CIK: 1497253
• Web: organovo.com
• Phone: (858) 224-1000
• Fax: N/A
• Employees: 11
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($4.47)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$13.84 million
• Net Margins: -11,016.07%
• Pretax Margin: -11,011.61%
• Return on Equity: -612.23%
• Return on Assets: -177.02%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.70
• Quick Ratio: 1.70

Sales & Book Value

• Annual Sales: $130 thousand
• Price / Sales: 17.36
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.42) per share
• Price / Book: -0.32

Miscellaneous

• Outstanding Shares: 16,590,000
• Free Float: 16,420,000
• Market Cap: $2.26 million
• Optionable: N/A
• Beta: 1.58